DocGo (DCGO) Q2 2025: Medical Transport Rises to 62% of Revenue as Migrant Wind-Down Reshapes Mix

2025-08-07 | By EarningsIQ Research

DocGo’s Q2 marks a strategic inflection as medical transportation now dominates 62% of total revenue, reflecting the sharp wind-down in migrant-related government work and a pivot toward payer, provider, and recurring health system contracts. Operational execution on cost controls and cash collections stabilized liquidity, but the business faces a critical transition period as it seeks to replace episodic revenue with scalable, tech-enabled care models. Management’s outlook hinges on ramping new contract volumes and converting care gap patients to higher-value services.

Summary

• Revenue Mix Transformation: Medical transportation now comprises the majority of revenue as government vertical contracts wind down.
• Cost Structure Reset: SG&A cuts and AR collections bolster cash, but margin pressure remains during the business model transition.
• Growth Engine Shifts: Payer and provider verticals must scale rapidly to offset lost government volume and restore profitability.

Performance Analysis

DocGo’s Q2 results were shaped by the sharp contraction of government vertical revenues, primarily due to the conclusion of migrant-related programs that had previously driven outsized top-line growth. Total revenue fell significantly year-over-year, with mobile health revenue declining to $30.8 million, reflecting the loss of approximately $98 million in migrant program revenue compared to the prior year. The company’s medical transportation segment, however, grew modestly to $49.6 million, now accounting for 62% of consolidated revenue, up from 29% a year ago, as the business pivots to more sustainable, recurring service lines.

Margin dynamics reflected this transition, with adjusted gross margin in mobile health at 32.5% (up sequentially, but down year-over-year) and medical transportation at 31.1% (a 200 basis point YoY improvement). However, adjusted EBITDA swung to a loss of $6.1 million, underscoring the drag from lower revenue scale and the lag in cost absorption as new contracts ramp. SG&A reductions, including a significant reduction in force and vendor renegotiations, yielded $10 million in annualized savings, but SG&A as a percentage of revenue remains elevated due to the lower revenue base.

• Cash Flow Inflection: $33.6 million in positive operating cash flow driven by rapid AR collections from legacy government contracts, with cash and equivalents rising to $128.7 million.
• Revenue Concentration Shift: Medical transportation’s share of total revenue increased to 62% as mobile health revenue contracted sharply.
• Margin Pressure: Gross margin improvement in transportation offset by lagging scale and ramp-up costs in new verticals.

The quarter’s results highlight the urgency for DocGo to accelerate its payer and provider business, as legacy government work becomes a smaller and less reliable contributor to performance.

Executive Commentary

Strategic Positioning

1. Medical Transportation as Core Revenue Driver

Medical transportation, patient transfer and non-emergency mobility services, now anchors DocGo’s revenue mix as the government vertical contracts fade. The business is scaling with new contracts, such as a major New York health system and the Albany Stratton VA Medical Center, and is targeting double-digit EBITDA margins. However, Q2 margins were suppressed by pre-launch hiring and onboarding costs, particularly in New York, as the company prepared for a July 1 contract start. Management expects transportation to remain 60–65% of revenue in 2025, but acknowledges the need for further margin expansion and operational leverage.

2. Payer and Provider Expansion and Care Gap Closure

The payer and provider vertical, proactive care delivery for insurance and health plan members, is positioned as DocGo’s primary growth engine. The company expanded its care gap closure program, now covering 1.2 million assigned lives (up from 900,000 last quarter), and reported a 50% increase in patient conversions QoQ. While this vertical is still early in scale, management sees significant cross-sell potential into primary care and transitional care services, with a pipeline of contracts under negotiation with top national payers. The challenge remains execution: converting eligible lives into revenue-generating visits and scaling field teams to meet rising demand.

3. Technology and AI-Driven Operational Efficiency

AI automation, software-driven scheduling and patient engagement, is being deployed to drive down cost-to-serve and improve patient conversion rates. A new text-based AI agent, launched in Q2, has already confirmed over 3,000 appointments and rescheduled 350, saving about 10% of live operator time. Management aims to further automate patient sign-ups and outreach, which could drive higher engagement and more efficient scaling as the business grows.

4. Cost Discipline and Balance Sheet Strengthening

SG&A rationalization, headcount reduction and vendor renegotiation, delivered $10 million in annualized savings and helped offset the revenue contraction. Aggressive AR collection from government contracts boosted liquidity, allowing DocGo to pay off $30 million in debt and extend its buyback program. This cash discipline is critical as the company navigates a lower-revenue environment and invests in new growth initiatives.

5. Selective Government and Population Health Work

Municipal population health, ongoing public health contracts, are now a smaller, more targeted focus. DocGo is prioritizing “evergreen” engagements, such as chronic disease management and behavioral health for underserved populations, over episodic emergency response. The company will break out this revenue segment going forward, but its contribution remains modest in the current mix.

Key Considerations

DocGo’s Q2 marks a turning point as the business pivots from episodic, high-margin government work to recurring, operationally intensive contracts in transportation and payer-provider services. Execution risk is elevated as the company must rapidly scale new business lines to restore profitability and sustain growth.

Key Considerations:

• Revenue Replacement Challenge: The wind-down of migrant-related government work removed a major revenue and margin contributor, putting pressure on new verticals to fill the gap.
• Margin Rebuilding Path: Early-stage payer-provider contracts and transportation launches carry ramp-up costs and utilization risk, delaying margin recovery despite cost cuts.
• Cash Flow Cushion: Strong AR collections and cash management provide a near-term buffer, but sustainable profitability depends on execution in core growth segments.
• Contract Pipeline Visibility: Management cites a robust pipeline and expanding relationships with top payers, but conversion to revenue remains dependent on operational scale and patient engagement.
• Technology Leverage: AI-driven process automation is beginning to drive efficiency, but the impact on cost structure and scalability will be a key metric to watch.

Risks

DocGo faces material execution risk as it transitions from high-margin, non-recurring government work to more competitive, lower-margin recurring contracts. Failure to scale payer-provider operations or delays in converting assigned lives to revenue-generating visits could extend the period of negative EBITDA. Additionally, reliance on a concentrated set of transportation contracts and the need to maintain high utilization rates introduces operational volatility. Regulatory changes in healthcare reimbursement or payer priorities could further impact growth trajectories.

Forward Outlook

For Q3 2025, DocGo expects:

• Continued ramp in medical transportation trip volumes, aided by the July 1 New York contract launch
• Ongoing expansion in care gap closure and primary care visits, with a target of 31,000 care gap visits by year-end

For full-year 2025, management maintained guidance:

• Positive adjusted EBITDA targeted in the back half of 2026, contingent on achieving $80–85 million quarterly revenue, 33–35% gross margins, and further SG&A reductions

Management highlighted several factors that will influence results:

• Speed of scaling field teams to meet rising care gap and transportation demand
• Ability to convert assigned lives into completed visits and cross-sell higher-value services

Takeaways

DocGo’s business model is undergoing a forced reset, with future performance tied to the pace of recurring contract scale and operational leverage.

• Core Revenue Realignment: Medical transportation is now the anchor business, but must deliver on margin expansion as payer-provider work ramps.
• Execution Over Narrative: Management’s bullish pipeline commentary must be matched by tangible conversion of assigned lives and contract ramp, as episodic government work fades.
• AI and Automation as a Wildcard: Early tech-driven efficiency gains are promising but unproven at scale; sustained cost discipline and cash flow management will be critical in the coming quarters.

Conclusion

DocGo’s Q2 underscores a critical business model transformation, as the company pivots from episodic, high-margin government contracts to recurring, operationally intensive transportation and payer-provider services. The balance sheet is stable, but the next phase will test DocGo’s ability to scale new verticals and rebuild margins in a more competitive, volume-driven environment.

Industry Read-Through

DocGo’s experience highlights the volatility faced by healthcare service providers reliant on episodic government contracts, underscoring the need for recurring revenue models and operational scalability. The sector is seeing a shift toward at-home and mobile care, with payers and health systems seeking partners that can deliver proactive, tech-enabled services at scale. Companies with robust technology platforms and the ability to integrate with payer workflows are best positioned, but execution risk remains high as the market transitions from emergency response to sustainable care delivery. Investors in healthcare services should monitor contract mix, utilization rates, and the pace of margin recovery as leading indicators of business health.

DCGO Healthcare Mobile health Medical transportation Payer-provider Recurring revenue AI automation Cost discipline